Pieter J. Strijkert
Chairman at Dynacorts Therapeutics BV
Network origin in Pieter J. Strijkert first degree
Entity | Entity type | Industry | |
---|---|---|---|
Janssen Vaccines & Prevention BV
Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Pieter J. Strijkert via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
GALAPAGOS NV | Biotechnology | Director/Board Member | |
University of Groningen | College/University | Doctorate Degree | |
Zambon Nederland BV
Zambon Nederland BV Pharmaceuticals: MajorHealth Technology Zambon Nederland BV operates as a pharmaceutical company. The company was founded in 1906 and is headquartered in Amersfoort, the Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Impatients NV
Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer | |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Miscellaneous Commercial Services | Founder |
Statistics
International
Netherlands | 6 |
Belgium | 2 |
Sectoral
Health Technology | 4 |
Commercial Services | 3 |
Consumer Services | 2 |
Operational
Chief Executive Officer | 3 |
President | 2 |
Director/Board Member | 2 |
Corporate Officer/Principal | 2 |
Founder | 2 |
Most connected contacts
Insiders | |
---|---|
Ronald H. P. Brus | 7 |
Sjaak Bot | 1 |
- Stock Market
- Insiders
- Pieter J. Strijkert
- Company connections